Elevated serum IL-6 and total IgEAb are associated with poor survival in natural killer/T-cell lymphoma

Ann Hematol. 2024 Apr;103(4):1285-1292. doi: 10.1007/s00277-023-05579-7. Epub 2023 Dec 14.

Abstract

Natural killer/T-cell lymphoma (NKTCL) is an aggressive and malignant condition with a high mortality rate. Prognostic factors may assist to evaluate the outcome of the disease and may also be useful in selecting appropriate therapeutic strategies for patients. The study aims to describe NKTCL in terms of its clinical features, laboratory examinations, and immunophenotypes and to analyze relevance affecting patient survival outcomes. The patients diagnosed as NKTCL in Jinling Hospital from Jan. 2012 to Dec. 2022 were reviewed retrospectively in this study basing on histopathology. The analysis was performed to evaluate overall survival (OS). A total of 125 NKTCL patients were included, which mainly affected male more than female with the onset median age of 51.00 years old (range, 14 ~ 85 y). NKTCL commonly affects the nasopharynx and upper aerodigestive tract, intestines, and skin. The median overall survival was 13.00 months (range, 2-156 m), and the 5-year survival rate was 9.8%. Under univariable analysis revealed the following factors at diagnosis age: serum total IgEAb ≥ 54.6 IU/mL, IL-6 ≥ 32.445 ng/L, elevated PINK score, smoking, and extranasopharyngeal site were statistically significant predictors for OS. Compared to the patients who received radiotherapy alone or chemotherapy alone, the patients who received combined chemoradiotherapy had longer OS. We found that IL-6 and total IgEAb were significant prognostic factors in NKTCL patients. Also, extranasopharyngeal site was correlated with advanced disease.

Keywords: Interleukin-6; Natural killer/T‐cell lymphoma; Overall survival; Prognostic; Total IgEAb.

MeSH terms

  • Adolescent
  • Female
  • Humans
  • Interleukin-6*
  • Killer Cells, Natural / pathology
  • Lymphoma, Extranodal NK-T-Cell* / diagnosis
  • Lymphoma, Extranodal NK-T-Cell* / pathology
  • Lymphoma, Extranodal NK-T-Cell* / therapy
  • Male
  • Neoplasm Staging
  • Prognosis
  • Retrospective Studies

Substances

  • Interleukin-6